Cutting Edge Therapeutics

Pharmaceutical Manufacturing • • 1-10 Employees

Company overview

Headquarters	XX
NAICS	3254
Keywords	Orphan Drugs, Neurology, Oncology, Infectious Diseases, Immunology, Fast Track, Early Stage Development
Founded	2010
Employees	1-10

Key Contact at Cutting Edge Therapeutics

Lisa Davidson

Owner

About Cutting Edge Therapeutics

Cutting Edge Therapeutics, Inc (CET) is a start-up biopharmaceutical company focused on licensing and developing a portfolio of exciting and innovative therapeutics for CNS disorders, Cancer and Infectious Diseases. We are dedicated to finding cutting edge treatments to address unmet medical needs worldwide. We are committed to building a portfolio of new therapies to meet the growing cases. CET is hoping to be the first to market novel therapeutics in the emerging field of oncology, neurology and immunotheraphy.

Cutting Edge Therapeutics revenue & valuation

Annual revenue	$85,555
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$273,776
Total funding	No funding

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Founder/Owner

Funding Data

Cutting Edge Therapeutics has never raised funding before.

Frequently asked questions

Cutting Edge Therapeutics is located in XX.

Cutting Edge Therapeutics was founded in 2010, making it 16 years old. The company has established itself as a significant player in its industry over this time.

Cutting Edge Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Cutting Edge Therapeutics

Lisa Davidson

Owner

4.8

40,000 users